GH secretagogues and uses thereof

Details GH secretagogues and uses thereof GH secretagogues and uses thereof

2008-01-08

2008-01-08

Tsang, Cecilia J. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07316997

ABSTRACT:
The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.

REFERENCES:
patent: 5861379 (1999-01-01), Ibea et al.
patent: 5939386 (1999-08-01), Ibea et al.
patent: 6020311 (2000-02-01), Brazeau et al.
patent: 6696063 (2004-02-01), Torres
patent: 2005/0197288 (2005-09-01), Abribat et al.
patent: 2367461 (2000-09-01), None
patent: WO 97/09060 (1997-03-01), None
patent: WO-00/14236 (2000-03-01), None
patent: WO 2005/037307 (2005-04-01), None
“Wasting syndrome treatment advocacy issues” http://www.medibolics.com/NewLipodystrophyDrug.htm.
Garcia-Viejo et al. “Strategies for treating HIV-related lipodystrophy,” Expert Opin., 2001, 10, 1443-56.
Nagaya, N., et al. 2005. Treatment of Cachexia with Ghrelin in Patients with COPD.Chest128(3): 1187-11193.
Falutz, J., et al. 2005. A Placibo-Controlled, Dose-Ranging Study of a Growth Hormone Releasing Factor in HIV-Infected Patients with Abdominal Fat Accumulation.AIDS19: 1279-1287.
Koutkia, P., et al. 2005. Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus—Infected Men with Fat Accumulation.The Journal of Clinical Endocrinology and Metabolism90(4): 2154-2160.
Theratechnologies Inc. 2004. Theratechnologies Presents Results from its HIV-Associated Lipodystrophy Phase II Study on THGRF at the 12thInternational Congress of Endocrinology. Online: www.theratech.com/en
ews-events
ews.
Khorram, O., et al. 1997. Effects of [Norleucine 27] Growth-Hormone-Releasing Hormone (GHRH) (1-29)-NH2 Administration on the Immune System of Aging Men and Women.Journal of Clinical Endocrinology and Metabolism82(11): 3590-3596.
Engelson, Ellen S., et al., “Effect of Recombinant Human Growth Hormone in the Treatment of Visceral Fat Accumulation in HIV Infection”, Journal of Acquired Immune Deficiency Syndromes, 2002, vol. 30, pp. 379-391.
Kotler, Donald P., et al., “Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients”, J. Acquir. Immune Defic. Syndr., Mar. 1, 2004, vol. 35, No. 3, pp. 239-252.
Rietschel, Petra, et al., “Assessment of Growth Hormone Dynamics in Human Immunodeficiency Virus-Relaetd Lipodystrophy”, The Journal of Clinical Endocrinology and Metabolism, 2001, vol. 86, No. 2, pp. 504-510.
Miller, Kirk D., et al., “Visceral abdominal-fat accumulation associated with use of indinavir”, The Lancet, Mar. 21, 1998, vol. 351, pp. 871-875.
Wanke, Christine, et al., “Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV”, AIDS, 1999, vol. 13, No. 15, pp. 2099-2103.
Lo, Joan C., et al., “The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation”, The Journal of Clinical Endrocrinology & Metabolism, 2001, vol. 86, No. 8, pp. 3480-3487.
Koutkia, Polyxeni, et al., “Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy”, JAMA, Jul. 14, 2004, vol. 292, No. 2, pp. 210-218.
Abribat, T., et al., “TH9507 A New Growth Hormone-Releasing Factor (GRF) Analogue is a Powerful Insulin-Like Growth Factor-1 (IGF-1) Inducer in 50-60 Years Old Healthy Subjects: A 7-Day, Randomized Multidose Study”, The Endocrine Society's 84 th Annual Meeting, 2001, Denver, p. P2-292.
Clemmons, David, et al., “Safety Assessment and Metabolic Effects of TH9507, a Growth Hormone-Releasing Factor Analogue (GRF), in Patients with Type 2 Diabetes Mellitus”, The Endocrine Society's 86th Annual Meeting, 2003, Philadelphia, p. P2-354.
Park, Y.W., et al., “Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass?” International Journal of Obesity, 2002, vol. 26, pp. 978-983.
Hadigan, Colleen, et al., “Metabolic Effects of Rosiglitazone in HIV Lipodystrophy”, Annals of Internal Medicine, May 2004, vol. 140, No. 10, pp. 786-794.
Hadigan, Colleen, et al., “Metformin in the Treatment of HIV Lipodystrophy Syndrome: A Randomized Controlled Trial”, JAMA, Jul. 26, 2000, vol. 284, No. 4, pp. 472-477.
Johannsson, Gudmundur, et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure”, Journal of Clinical Endrocrinology and Metabolism, 1997, vol. 82, No. 3, pp. 727-734.
Calao, Annamaria, et al., “Improved Cardiovascular Risk Factors and Cardiac Performance after 12 Months of Growth Hormone (GH) Replacement in Young Adult Patients with GH Deficiency”, The Journal of Clinical Endocrinology & Metabolism, 2001, vol. 86, No. 5, pp. 1874-1881.
Thornton, P.L., et al., “Chronic [D-Ala{circumflex over ( )}2]GHRH administration increases working memory in aged animals”, Abstracts of the Society for Neuroscience, vol. 23, No. 1, 1997, p. 532.
Alvarez, X.A., et al., “Effects of GRF (1-29) NH2 on Short-Term Memory: Neuroendocrine and Neuropsychological Assessment in Healthy Young Subjects”, Meth. Find. Exp. Clin. Pharmacol., 1990, vol. 12, No. 7, pp. 493-499.
Schneider-Rivas, Sonia, et al., “Modulation of Long-Term Memory and Extinction Responses Induced By Growth Hormone (GH) and Growth Hormone Releasing Hormone (GHRH) in Rats”, Life Sciences, vol. 56, No. 22, 1995, pp. 433-441.
Aleman, Andre, et al., “Insulin-Like Growth Factor-I and Cognitive Function in Healthy Older Men”, Journal of Clinical Endocrinology and Metabolism, vol. 84, No. 2, 1999, pp. 471-475.
Theratechnologies Inc., “ThGRF in HIV-related lipodystrophy: Phase II clinical trial in Canada and the US”, May 22, 2003, http://www.medibolics.com/NewLipodystrophyDrug.htm.
Theratechnologies Press Releases, “Theratechnologies clinically demonstrates improvement in immune function among elderly with ThGRF peptide”, Jun. 6, 2002, pp. 1-3, http://www.theratech.com/english/press/2002/0606-2002.htm.
Carr, Andrew, et al., “A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors”, AIDS, 1998, vol. 12, pp. F51-F58.
Hadigan, Colleen, et al., “Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy”, Clin. Infect. Dis., 2001, vol. 32, No. 1, pp. 130-139.
Friis-Moller, et al., “Combinatino Antiretroviral Therapy and the Risk of Myocardial Infarction”, The New England Journal of Medicine, Nov. 2003, vol. 349, No. 21, pp. 1993-2003.
Pouliot, Marie-Christine, et al., “Visceral Obesity in Men: Associations with Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels”, Diabetes, vol. 41, Jul. 1992, pp. 826-834.
Meininger, Gary, et al., “Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men{circumflex over ( )}1-3”, Am. J. Clin. Nutr., 2002, vol. 76, pp. 460-465.
Koutkia, Polyxeni, et al., “Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodrystrophy”, Am. J. Physiol. Endocrinol. Metab., 2004.
Chen et al., 2002, J. Clin. Endocrinol. Metabolism 97:4845-4856.
Kato et al., 2002, Internal Medicine; 41:7-13.
Koutkia et al., 2004, Am. J. Physiol. Endocrinol. Metab. 286: E296-303 (publication date Oct. 14, 2003).
Meininger et al., 2002, Metabolism 51:260-266.
Mulro

Affiliated with

Also associated with

Rating

GH secretagogues and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GH secretagogues and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GH secretagogues and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2801439